Dr. Edwards is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM). She maintains a clinical practice in hematology at Boston Medical Center (BMC) with a specific research interest in plasma cell disorders such as systemic immunoglobulin light chain (AL) amyloidosis. She is committed to improving the care of vulnerable patient populations using her translational research platform to address unanswered questions encountered in clinical care. After internal medicine residency, she completed hematology and oncology fellowship at BUSM/BMC, obtaining rigorous training through the comprehensive cancer center and the world-renowned BU Amyloidosis Center. Her current research, a collaboration with the Center for Regenerative Medicine (CReM) and BU Amyloidosis Center, focuses on using novel disease models for hematologic malignancies to study the earliest signs of disease, test treatments and develop the most promising therapeutic agents for clinical trials. She is also an active mentor for students and residents, and has a strong passion for teaching and mentoring trainees.
Diversity, Equity, Inclusion and Accessibility
I am part of a dedicated team of healthcare professionals, researchers, students and staff from different countries and various regions of the U.S. The culture of our Section is defined by the unique perspectives that we each bring with us. As both a large academic medical center and safety-net hospital serving the communities of Boston and its surroundings, our trainees engage in cutting edge research and gain real-world clinical experience by caring for local underserved populations. Our multilingual team is committed to promoting cultural competency, equity and inclusion in science, medicine and healthcare. We strive to maintain a workforce that is as diverse as the communities we serve, and aim to create a safe space for our members to learn, grow and succeed in their life goals. Acknowledging that we all have a role to play, I am dedicated to welcoming and celebrating individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation, veteran status, and national origin.
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Defining a molecular signature of cardiotoxicity in systemic immunoglobulin light chain amyloidosis02/15/2023 - 12/31/2023 (PI)
International Myeloma Foundation
SPORE in Multiple Myeloma06/01/2021 - 05/31/2023 (Subcontract PI)
Dana-Farber Cancer Institute NIH NCI5P50CA100707-19
Defining a molecular signature of cardiac tissue dysfunction in systemic immunoglobulin light-chain amyloidosis07/01/2020 - 06/30/2022 (PI)
American Society of Hematology
M13-494: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma10/21/2020 - 10/20/2023 (PI)
AbbVie Inc.
|
Yr
|
Title
|
Project-Sub Proj
|
Pubs
|
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Horwitz MEM, Edwards CV, Athavale P, McCloskey L, Cabral HJ, Benjamin EJ, Handley MA. The STAR-MAMA RCT: Bilingual Mobile Health Coaching for Postpartum Weight Loss. Am J Prev Med. 2023 Apr 05.View Related Profiles. PMID: 37028566
-
-
Murray Horwitz ME, Prifti CA, Battaglia TA, Ajayi AT, Edwards CV, Benjamin EJ, Yarrington CD, Parker SE. Prepregnancy Cardiovascular Disease Risk Factors and Adverse Pregnancy Outcomes in a Safety-Net Hospital. J Womens Health (Larchmt). 2023 Apr; 32(4):401-408.View Related Profiles. PMID: 36827080; DOI: 10.1089/jwh.2022.0322;
-
-
-
La J, DuMontier C, Hassan H, Abdallah M, Edwards C, Verma K, Ferri G, Dharne M, Yildirim C, Corrigan J, Gaziano JM, Do NV, Brophy MT, Driver JA, Munshi NC, Fillmore NR. Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiol Drug Saf. 2023 May; 32(5):558-566.View Related Profiles. PMID: 36458420
-
Horta LFB, Edwards CV, Kaku MC, Lau KHV. Clinical Reasoning: A 67-Year-Old Woman With Progressive Tingling Sensations and Imbalance. Neurology. 2023 Jan 17; 100(3):151-157.View Related Profiles. PMID: 36302667
-
Edwards CV, Sheikh AR, Dennis MJ, Hunter A, Mackay ZP, Catudal EC, Elias R, Cabral HJ, Sarosiek SR, Tapan U. The impact of substance use on health care utilization, treatment, and outcomes in patients with non-small cell lung cancer. J Thorac Dis. 2022 Oct; 14(10):3865-3875.View Related Profiles. PMID: 36389291; PMCID: PMC9641327; DOI: 10.21037/jtd-21-1992;
-
Hassan H, Verma K, Ferri G, Brauneis D, Quillen K, Sloan JM, Sanchorawala V, Edwards CV. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Transplant Cell Ther. 2022 Nov; 28(11):761.e1-761.e7.View Related Profiles. PMID: 35970300
-
Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199.View Related Profiles. PMID: 35731907
Showing 10 of 16 results.
Show More
-
Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22(8):566-568.View Related Profiles. PMID: 35367193
-
Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 12 23; 138(25):2632-2641. PMID: 34521113; PMCID: PMC8703360; DOI: 10.1182/blood.2020009039;
-
Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab. Am J Hematol. 2022 01 01; 97(1):79-89.View Related Profiles. PMID: 34739735
-
Edwards CV, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Wall JS, Solomon A, Eisenberger A, Lentzsch S. One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2019; 26(sup1):115-116. PMID: 31343323
-
Nwabudike SM, Edwards CV, Akinboro O, Quinn K, Sarosiek S, Ko N. Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer. Case Rep Hematol. 2018; 2018:9249506.View Related Profiles. PMID: 30647983; PMCID: PMC6311830; DOI: 10.1155/2018/9249506;
-
Edwards C, Sideeg A, Kunadu A, Sammut A, Redwood E. Adult- onset Still’s Disease. American College of Physicians Hospitalist Journal. 2016; 35-36.
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 7 |
| 2023 | 4 |
2020-2021 Boston University:
American Society of Hematology Research Training Award
2019 Boston University School of Medicine:
Residents’ Teaching Award
2018 Boston University School of Medicine:
Fellow Immersion Training in Addiction Medicine Scholarship Award
2017 Amyloidosis Foundation:
Junior Researcher Travel Award for the XVIth Annual Symposium